Global Neurology Academy

Multiple Sclerosis: Continuity of Care from Diagnosis Through Disability

    Multiple sclerosis is an often devastating disease for patients and their families. With the recent emergence of potential disease modifying therap...
    • Overview

      Multiple sclerosis is an often devastating disease for patients and their families. With the recent emergence of potential disease modifying therapies, early and correct diagnosis is the new cornerstone for standard-of-care, as well as the new baseline from which hope has grown for 1) effective treatments; and 2) quality of life maintenance. Central in this effort is appreciation of clinical, environment and genetic, and paraclinical prognostic indicators with a focused appreciation for what magnetic resonance imaging is bringing to this effort. But MS care is more than just a correct and timely diagnosis, it includes the need for a multidisciplinary team of physicians and other health care personnel who collectively optimize the outcome for each individual patient. As such, educational and practice needs have been identified that are addressed in this initial series of three modules written, and reviewed by global faculty.

      This module offers for the participant an overview of MS; diagnostic strategies and identifying predictors of outcome; and links disease and disability progression in a way that provides insight into clinical practice.

    • Learning Objectives

      At the completion of this module, participants will be better able to:

      1. Understand the natural history of MS and the socioeconomic and personal disabilities associated with this disease
      2. Make a differential, positive diagnosis of MS and identify in each patient potential predictors of long-term outcome
      3. Link disease and disability progression in patients with MS, and assess the importance of magnetic resonance imaging in this process
    • Commercial Support

      This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.
       
      Original Release Date: 16 February 2015
      Expiration Date: 16 February 2017

    • Disclosure of Conflicts of Interest

      Course Director

      Gavin Giovannoni, MBBCh, PhD
      Professor of Neurology
      Centre Lead for Neuroscience and Trauma
      Barts and the London
      London, United Kingdom
      Financial Relationship Disclosure
      Steering Committee: AbbVie, Biogen-Idec, Novartis, TEVA, Roche
      Consultant: Biogen-Idec, GW Pharma, Merck-Serono, Novartis, Genzyme Sanofi, Fiveprime, Ironwood, Synthon BV, Vertex Pharmaceuticals
      Clinical Advisor: Canbex

      Author

      Gavin Giovannoni, MBBCh, PhD
      Professor of Neurology
      Centre Lead for Neuroscience and Trauma
      Barts and the London
      London, United Kingdom
      Financial Relationship Disclosure
      Steering Committee: AbbVie, Biogen-Idec, Novartis, TEVA, Roche
      Consultant: Biogen-Idec, GW Pharma, Merck-Serono, Novartis, Genzyme Sanofi, Fiveprime, Ironwood, Synthon BV, Vertex Pharmaceuticals
      Clinical Advisor: Canbex

      Reviewer

      J. Theodore Phillips, MD, PhD, FAAN
      Attending Neurologist
      Baylor University Medical Center
      Dallas, TX
      Financial Relationship Disclosure
      Grant support: Biogen Idec, Roche
      Consultant: Acorda, Biogen Idec, Genzyme, Merck-Serono, Sanofi Aventis, Xenoport
      Speaker's Bureau: Acorda, Biogen Idec, Genzyme, Sanofi Aventis

    Facebook Comments

    Sign-up for the Global Neurology Academy newsletters.
    Comprehensive Neurology Education.

    Better education for a better you.

    * Required
    Optional